Sofosbuvir
ATC J05AP08 · 12 markets · 81 records
US 15 records · 4 strengths
GB 15 records · 4 strengths
- 400 mgtabletEpclusaHarvoni、Sovaldi、Vosevi、Manufacturer: Gilead Sciences Ltd
- 200 mgtabletEpclusaHarvoni、Sovaldi
- 200 mgpowderEpclusa 200mg/50mg granules sachetsHarvoni 33.75mg/150mg granules sachets、Sovaldi 150mg granules sachets
- 150 mgpowderEpclusa 200mg/50mg granules sachetsHarvoni 33.75mg/150mg granules sachets、Sovaldi 150mg granules sachets
CN 9 records · 1 strengths
- 400 mgtablet索华迪索磷布韦Manufacturer: 北京凯因格领生物技术有限公司、Manufacturer: 南京正大天晴制药有限公司、Manufacturer: 吉林四环制药有限公司、Manufacturer: 山东世博金都药业有限公司
AU 8 records · 2 strengths
- 400 mgtabletEpclusaEPCLUSA sofosbuvir 400 mg / velpatasvir 100 mg tablet bottle、HARVONI ledipasvir/sofosbuvir 90 mg/400 mg tablet bottle、Vosevi、VOSEVI sofosbuvir (400 mg), velpatasvir (100 mg), voxilaprevir (100 mg) tablet bottle
3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
ES 8 records · 4 strengths
FR 7 records · 4 strengths
- 400 mgtabletEPCLUSA 200 mg/50 mg, comprimé pelliculéHARVONI 90 mg/400 mg, comprimé pelliculé、SOVALDI 400 mg, comprimé pelliculé、VOSEVI 400 mg/100 mg/100 mg, comprimé pelliculé
- 200 mgtabletEPCLUSA 200 mg/50 mg, comprimé pelliculé
- 200 mgpowderEPCLUSA 150 mg/37,5 mg, granulés enrobés en sachet
- 150 mgpowderEPCLUSA 150 mg/37,5 mg, granulés enrobés en sachet
CA 4 records · 1 strengths
- 400 mgtabletEpclusaHarvoni、Sovaldi、Vosevi
TW 4 records · 2 strengths
- 400 mgtabletSovaldi索華迪400毫克膜衣錠
3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
EU 4 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
4 records · 0 manufacturers 4 registros · 0 fabricantes 4 个记录 · 0 个厂家 4 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
SG 2 records · 1 strengths
- 400 mgtabletEpclusaVosevi
HK 2 records · 1 strengths
2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
MX 1 records · 1 strengths
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
| Strength / form / release | US | GB | CA | AU | SG | CN | ES | MX | TW | HK | EU | FR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 400 mgRecorded as: 0.4 g tablet | Manufacturer: Asegua Therapeutics LLC Epclusa Harvoni | Manufacturer: Gilead Sciences Ltd ×2 Epclusa Harvoni | Epclusa Harvoni Sovaldi+1Vosevi | Epclusa EPCLUSA sofosbuvir 400 mg / velpatasvir 100 mg tablet bottle HARVONI ledipasvir/sofosbuvir 90 mg/400 mg tablet bottle+2Vosevi VOSEVI sofosbuvir (400 mg), velpatasvir (100 mg), voxilaprevir (100 mg) tablet bottle | Epclusa Vosevi | Manufacturer: 北京凯因格领生物技术有限公司 ×2 Manufacturer: 南京正大天晴制药有限公司 Manufacturer: 吉林四环制药有限公司+2Manufacturer: 山东世博金都药业有限公司 ×4 索华迪索磷布韦 | Epclusa Harvoni Sovaldi | Sovaldi 索華迪400毫克膜衣錠 | EPCLUSA 200 mg/50 mg, comprimé pelliculé HARVONI 90 mg/400 mg, comprimé pelliculé SOVALDI 400 mg, comprimé pelliculé+1VOSEVI 400 mg/100 mg/100 mg, comprimé pelliculé | |||
| 200 mg tablet | Epclusa Harvoni Sovaldi | Epclusa Harvoni Sovaldi | EPCLUSA 200 mg/50 mg, comprimé pelliculé | |||||||||
| 200 mg powder | Epclusa 200mg/50mg granules sachets Harvoni 33.75mg/150mg granules sachets Sovaldi 150mg granules sachets | EPCLUSA 150 mg/37,5 mg, granulés enrobés en sachet | ||||||||||
| 150 mg powder | Epclusa 200mg/50mg granules sachets Harvoni 33.75mg/150mg granules sachets Sovaldi 150mg granules sachets | EPCLUSA 150 mg/37,5 mg, granulés enrobés en sachet | ||||||||||
| 200 mg pellet | Epclusa Harvoni Sovaldi | |||||||||||
| 150 mg pellet | Epclusa Harvoni Sovaldi | |||||||||||
| 100 mg tablet | Vosevi | |||||||||||
| 200 mg liquid | Epclusa | |||||||||||
| 150 mg liquid | Epclusa | |||||||||||
unknown | Epclusa Harvoni Vosevi | Epclusa Vosevi | Epclusa Harvoni Sovaldi+1Vosevi | |||||||||
tablet | Vosevi | Epclusa Harvoni Vosevi |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
4 more strength/form rows are recorded only in ES · MX · TW and are not shown in this table. Hay 4 filas de concentración/forma registradas solo en ES · MX · TW que no se muestran en esta tabla. 另有 4 个规格/剂型仅在 ES · MX · TW 有记录（未在本表显示）。 另有 4 個規格/劑型僅在 ES · MX · TW 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Also called: 索非布費、索非布韋 nickname
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.